Author

A. Maraver

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

J. Colinge· 2 shared A. Bellahcene· 1 shared A. Casanova· 1 shared A. Castet-Nicolas· 1 shared A. Djiane· 1 shared A. Pradines· 1 shared A. Turtoi· 1 shared B. Chiavarina· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Colinge

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

RIP140 regulates HES1 oscillatory expression and mitogenic activity in colon cancer cells

N. Sfeir, M. Kajdan, S. Jalaguier, S. Bonnet, C. Teyssier, S. Pyrdziak, R. Yuan, E. Bousquet, A. Maraver, F. Bernex, N. Pirot, F. Boissiere, A. Castet-Nicolas, M. Lapierre, V. Cavailles

This study shows RIP140 regulates HES1 expression and mitogenic activity in colon cancer cells, with implications for patient survival.

bioRxiv · May 13, 2023 · PreprintCancer Biology

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC

S. Figarol, C. Delahaye, R. Gence, R. Asslan, S. Pagano, C. Tardy, J. Colinge, J.-P. Villemin, A. Maraver, I. Ferrer, L. Paz-Ares, I. Lajoie-Mazenc, E. Clermont, A. Casanova, A. Pradines, , G. Favre

This study identifies early escapers as a rare cell population resistant to EGFR-TKi and shows that tipifarnib overcomes this resistance by targeting Rho/ROCK pathway and preventing relapse.

bioRxiv · Apr 1, 2022 · PreprintCancer Biology

Tumor-Antagonizing Fibroblasts Secrete Prolargin as Tumor Suppressor in Hepatocellular Carcinoma

B. Chiavarina, R. Ronca, Y. Otaka, R. B. Sutton, S. Rezzola, T. Yokobori, P. Chiodelli, R. Souche, A. Maraver, G. Faa, T. Oyama, S. Gofflot, A. Bellahcene, O. Detry, P. Delvenne, , A. Turtoi

The paper identifies prolargin as a tumor suppressor secreted by tumor-antagonizing fibroblasts in HCC, showing its correlation with patient outcomes and its inhibition of tumor progression.

bioRxiv · Jan 4, 2021 · PreprintCancer Biology

MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis

D. Kantar, E. Bousquet Mur, M. Mancini, V. Slaninova, Y. Ben Salah, L. Costa, E. Forest, P. Lassus, C. Geminard, F. Boissiere-Michot, B. Orsetti, C. Theillet, J. Colinge, C. Benistant, A. Maraver, , A. Djiane

The paper shows that MAGI1 loss in luminal breast cancer promotes tumorigenesis by activating the AMOTL2/p38 stress pathway, which is inhibited by MAGI1.

bioRxiv · Jun 13, 2020Cancer Biology